Elevating theranostics:The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers  

作　　者：Claudia Chambers Broc Chitwood Charles J.Smith Yubin Miao 

机构地区：[1]Molecular Imaging and Theranostics Center,Columbia,Missouri,USA [2]Research Division,Harry S.Truman Memorial Veterans'Hospital,Columbia,Missouri,USA [3]Department of Chemistry,University of Missouri,Columbia,Missouri,USA [4]Department of Radiology,University of Missouri School of Medicine,Columbia,Missouri,USA [5]University of Missouri Research Reactor Center,University of Missouri,Columbia,Missouri,USA [6]Department of Radiology,University of Colorado Denver,Aurora,Colorado,USA

出　　处：《iRADIOLOGY》2024年第2期128-155,共28页融合影像学(英文)

基　　金：NIH Research Evaluation and Commercilization Hub,Grant/Award Number:1U01HL152410;USVA Medical Research Service,Grant/Award Number:I01 BX00096409;National Institutes of Health,Grant/Award Numbers:R01CA269221,R01CA225837。

摘　　要：Optimal therapeutic and diagnostic efficacy is essential for healthcare's global mission of advancing oncologic drug development.Accurate diagnosis and detection are crucial prerequisites for effective risk stratification and person-alized patient care in clinical oncology.A paradigm shift is emerging with the promise of multi-receptor-targeting compounds.While existing detection and staging methods have demonstrated some success,the traditional approach of monotherapy is being reevaluated to enhance therapeutic effectiveness.Het-erodimeric site-specific agents are a versatile solution by targeting two distinct biomarkers with a single theranostic agent.This review describes the inno-vation of dual-targeting compounds,examining their design strategies,thera-peutic implications,and the promising path they present for addressing complex diseases.

关 键 词：HETERODIMER heterobivalent hybrid peptide PSMA GRPR ΑVΒ3 SST MSH 

分 类 号：R73[医药卫生—肿瘤]